Results 21 to 30 of about 35,569 (305)

The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis.

PLoS ONE, 2015
AimsTo determine the effects of glucagon-like peptide-1 receptor agonists compared with placebo and other anti-diabetic agents on weight loss in overweight or obese patients with type 2 diabetes mellitus.MethodsElectronic searches were conducted for ...
Jessica E Potts, Laura J Gray, Emer M Brady, Kamlesh Khunti, Melanie J Davies, Danielle H Bodicoat   +5 more
doaj   +1 more source

An Exceedingly Rare Case of Liraglutide-Induced Liver Injury

Case Reports in Gastrointestinal Medicine, 2021
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the treatment of type 2 diabetes mellitus. We are reporting the second case of liraglutide-induced liver injury, with complete resolution of liver injury after discontinuation of ...
Swetha Parvataneni, Rajarajeshwari Ramachandran, Eric Then, Tyler Grantham, Vinaya Gaduputi   +4 more
doaj   +1 more source

Small-molecule agonists for the glucagon-like peptide 1 receptor [PDF]

Proceedings of the National Academy of Sciences, 2007
The peptide hormone glucagon-like peptide (GLP)-1 has important actions resulting in glucose lowering along with weight loss in patients with type 2 diabetes. As a peptide hormone, GLP-1 has to be administered by injection. Only a few small-molecule agonists to peptide hormone receptors have been described and none in the B family of the G protein ...
Knudsen, Lotte Bjerre, Kiel, Dan, Teng, Min, Behrens, Carsten, Bhumralkar, Dilip, Kodra, János T, Holst, Jens Juul, Jeppesen, Claus B, Johnson, Michael D, de Jong, Johannes Cornelis, Jorgensen, Anker Steen, Kercher, Tim, Kostrowicki, Jarek, Madsen, Peter, Olesen, Preben H, Petersen, Jacob S, Poulsen, Fritz, Sidelmann, Ulla G, Sturis, Jeppe, Truesdale, Larry, May, John, Lau, Jesper   +21 more
openaire   +3 more sources

Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity?

, 2023
Introduction: Despite there being a wide range of medicines available for the treatment of type 2 diabetes, the high rate of mortality suggests treatment needs to be improved.
Sheila A Doggrell, Doggrell, Sheila A
core   +1 more source

A Health Technology Assessment Based on Chinese Guidelines: Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Type 2 Diabetes Complicated with Cardiovascular Disease

Therapeutics and Clinical Risk Management, 2022
Zeyu Xie, Jinjian Li, Sensen Yang, Weishang Deng, Jisheng Chen Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, People’s Republic of ChinaCorrespondence: Jisheng Chen, Key Specialty of ...
Xie Z, Li J, Yang S, Deng W, Chen J
doaj  

Glucagon-like peptide-1 receptor agonist versus basal insulin in type-2 diabetic patients: An efficacy and safety analysis

, 2020
Purpose: To compare the effectiveness of glucagon-like peptide 1 receptor agonist with that of basal insulin in type 2 diabetes patients. Methods: Type-2 diabetes patients who were insensitive to metformin were treated with glucagon-like peptide 1 ...
Chen, Xiaxia, Lv, Qi, Lin, Kaiping, Lin, Ting, Yang, Xiaoling, Feng, Min   +5 more
core   +1 more source

The binding and activation of the glucagon-like peptide-1 receptor by exendin-4 [PDF]

, 2010
Background and purpose Exendin-4 (EX4) has the same physiological properties as glucagon-like peptide-1 (7-36)amide (GLP-1). EX4 has 50% identity with GLP-1, with an extra nine amino acids at its C-terminus.
Nasr, Elsayed Mohammed Nasr
core  

Canagliflozin Alleviates Diabetic Glomerular Endothelial Injury via Melibiose in a Microbiota‐Dependent Manner

Advanced Science, EarlyView.
Canagliflozin treatment reshapes the gut microbiota in DKD and elevates levels of melibiose, a metabolite derived from Roseburia intestinalis. Melibiose directly binds to and enhances the enzymatic activity of glyoxalase 1, leading to decreased methylglyoxal accumulation.
Wei Zhang, Yi Song, Changkun Li, Yuanyuan Luo, Mingwei Shao, Feng Guo, Fangyi Wei, Xunjie Fan, Wenwen Guo, Fengmei Xu, Yanhong Sang, Dongming Zhang, Yanhong Zhou, Lianwei Wang, Zhiqiang Kang, Yingjun Yang, Chunhua Song, Yanxia Liu, Xiaojun Ma, Jiao Wang, Chong Li, Shengnan Ma, Lin Zhao, Zhi Qin, Guolan Xing, Qiubo Zhao, Jun Li, Shumin Song, Dan Zhao, Ting Huang, Qingzhu Wang, Yanyan Zhao, Guijun Qin   +32 more
wiley   +1 more source

Semaglutide versus Tirzepatide - comparison of both drugs in treatment of diabetes type 2 and weight reduction

Quality in Sport
In recent years, the popularity of drugs which were firstly introduced as treatment for diabetes type 2 has surged, because of their’s significant effect of managing the body weight especially for patients that suffer for diabetes type 2.
Arkadiusz Staroń, Patrycja Karkos, Katarzyna Kuśmierczyk, Bartłomiej Gastoł, Karolina Mikołap, Marta Kras, Marta Jurga   +6 more
doaj   +1 more source

Cardioprotective Actions of a Glucagon‐like Peptide‐1 Receptor Agonist on Hearts Donated After Circulatory Death

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023
Background Heart transplantation with a donation after circulatory death (DCD) heart is complicated by substantial organ ischemia and ischemia–reperfusion injury. Exenatide, a glucagon‐like peptide−1 receptor agonist, manifests protection against cardiac
Sachiko Kadowaki, M. Ahsan Siraj, Weiden Chen, Jian Wang, Marlee Parker, Anita Nagy, Chun‐Po Steve Fan, Kyle Runeckles, Jing Li, Junko Kobayashi, Christoph Haller, Mansoor Husain, Osami Honjo   +12 more
doaj   +1 more source